Export citation

Show simple item record

dc.contributor.authorPinto, Joana*
dc.contributor.authorCarvalho, Márcia*
dc.contributor.authorDe Pinho, Paula Guedes*
dc.date.accessioned2021-02-11T09:28:15Z
dc.date.available2021-02-11T09:28:15Z
dc.date.issued2019*
dc.date.submitted2019-12-09 11:49:15*
dc.identifier42514*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/42643
dc.description.abstractThe metabolomics approach, defined as the study of all endogenously-produced low-molecular-weight compounds, appeared as a promising strategy to define new cancer biomarkers. Information obtained from metabolomic data can help to highlight disrupted cellular pathways and, consequently, contribute to the development of new-targeted therapies and the optimization of therapeutics. Therefore, metabolomic research may be more clinically translatable than other omics approaches, since metabolites are closely related to the phenotype and the metabolome is sensitive to many factors. Metabolomics seems promising to identify key metabolic pathways characterizing features of pathological and physiological states. Thus, knowing that tumor metabolism markedly differs from the metabolism of normal cells, the use of metabolomics is ideally suited for biomarker research. Some works have already focused on the application of metabolomic approaches to different cancers, namely lung, breast and liver, using urine, exhaled breath and blood. In this Special Issue we contribute to a more complete understanding of cancer disease using metabolomics approaches.*
dc.languageEnglish*
dc.subjectQH301-705.5*
dc.subjectQD415-436*
dc.subjectQ1-390*
dc.subject.othercell transporters*
dc.subject.otherpharmacodynamics*
dc.subject.othercell growth*
dc.subject.otherin vitro study*
dc.subject.othermetabolomic signatures*
dc.subject.otherendometabolome*
dc.subject.otherlung cancer*
dc.subject.othermetabolomics*
dc.subject.otherchemometric methods*
dc.subject.otherbladder cancer*
dc.subject.othermTOR*
dc.subject.othermetabolite profiling*
dc.subject.othermetabolic pathways*
dc.subject.otherhepatocellular carcinoma*
dc.subject.otherglutamate*
dc.subject.othersenescence MCF7*
dc.subject.otherbreath analysis*
dc.subject.otherbio actives*
dc.subject.otherbiomarker*
dc.subject.othergas chromatography–mass spectrometry (GC–MS)*
dc.subject.otherGC-MS*
dc.subject.otherlung*
dc.subject.otheromics*
dc.subject.othernutraceuticals*
dc.subject.otherglutaminase*
dc.subject.othermetabolism*
dc.subject.otheracylcarnitines*
dc.subject.otherErwinaze*
dc.subject.otherKidrolase*
dc.subject.otherglutathione*
dc.subject.othertargeted metabolomics*
dc.subject.otherapoptosis*
dc.subject.otherSLC1A5*
dc.subject.otheressential amino acids*
dc.subject.othercancer progression*
dc.subject.otherASCT2*
dc.subject.otherHR MAS*
dc.subject.otheralanine*
dc.subject.otheranalytical platforms*
dc.subject.othervolatile organic compound*
dc.subject.otherglutaminolysis*
dc.subject.otherisotope tracing analysis*
dc.subject.otherasparaginase*
dc.subject.othervitamin E*
dc.subject.otherbreast cancer*
dc.subject.otherprognosis*
dc.subject.otherearly diagnosis*
dc.subject.othertocotrienols*
dc.subject.otherNMR*
dc.subject.otherprostate cancer*
dc.subject.otherin vitro*
dc.subject.othercancer*
dc.subject.otherMDA-MB-231*
dc.titleCancer Metabolomics 2018*
dc.typebook
oapen.identifier.doi10.3390/books978-3-03921-346-7*
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0*
virtual.oapen_relation_isPublishedBy.publisher_nameMDPI - Multidisciplinary Digital Publishing Institute
virtual.oapen_relation_isPublishedBy.publisher_websitewww.mdpi.com/books
oapen.relation.isbn9783039213450*
oapen.relation.isbn9783039213467*
oapen.pages184*
oapen.edition1st*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/